nodes	percent_of_prediction	percent_of_DWPC	metapath
Cabergoline—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0381	0.126	CbGbCtD
Cabergoline—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0358	0.119	CbGbCtD
Cabergoline—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0358	0.119	CbGbCtD
Cabergoline—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0324	0.107	CbGbCtD
Cabergoline—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0324	0.107	CbGbCtD
Cabergoline—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0279	0.0925	CbGbCtD
Cabergoline—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0271	0.0898	CbGbCtD
Cabergoline—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0245	0.0812	CbGbCtD
Cabergoline—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0245	0.0812	CbGbCtD
Cabergoline—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0235	0.0779	CbGbCtD
Cabergoline—DRD1—nerve—acquired immunodeficiency syndrome	0.00555	0.0498	CbGeAlD
Cabergoline—HTR7—nerve—acquired immunodeficiency syndrome	0.00347	0.0311	CbGeAlD
Cabergoline—DRD2—nerve—acquired immunodeficiency syndrome	0.00328	0.0294	CbGeAlD
Cabergoline—HTR7—endothelium—acquired immunodeficiency syndrome	0.00295	0.0265	CbGeAlD
Cabergoline—HTR1A—blood plasma—acquired immunodeficiency syndrome	0.00275	0.0246	CbGeAlD
Cabergoline—HTR7—blood plasma—acquired immunodeficiency syndrome	0.00262	0.0236	CbGeAlD
Cabergoline—HTR2A—nerve—acquired immunodeficiency syndrome	0.00216	0.0194	CbGeAlD
Cabergoline—DRD5—lymphoid tissue—acquired immunodeficiency syndrome	0.00214	0.0192	CbGeAlD
Cabergoline—ADRA2A—blood plasma—acquired immunodeficiency syndrome	0.00192	0.0173	CbGeAlD
Cabergoline—DRD4—brain—acquired immunodeficiency syndrome	0.0019	0.017	CbGeAlD
Cabergoline—HTR2A—endothelium—acquired immunodeficiency syndrome	0.00184	0.0165	CbGeAlD
Cabergoline—DRD3—nervous system—acquired immunodeficiency syndrome	0.00174	0.0157	CbGeAlD
Cabergoline—DRD3—central nervous system—acquired immunodeficiency syndrome	0.00168	0.0151	CbGeAlD
Cabergoline—HTR2A—blood plasma—acquired immunodeficiency syndrome	0.00164	0.0147	CbGeAlD
Cabergoline—DRD5—nervous system—acquired immunodeficiency syndrome	0.00163	0.0147	CbGeAlD
Cabergoline—DRD5—central nervous system—acquired immunodeficiency syndrome	0.00157	0.0141	CbGeAlD
Cabergoline—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.00151	0.0136	CbGeAlD
Cabergoline—HTR2B—skin of body—acquired immunodeficiency syndrome	0.00147	0.0132	CbGeAlD
Cabergoline—DRD2—retina—acquired immunodeficiency syndrome	0.00136	0.0122	CbGeAlD
Cabergoline—ADRA1B—nervous system—acquired immunodeficiency syndrome	0.00134	0.012	CbGeAlD
Cabergoline—DRD3—brain—acquired immunodeficiency syndrome	0.00133	0.012	CbGeAlD
Cabergoline—ADRA1D—nervous system—acquired immunodeficiency syndrome	0.00131	0.0118	CbGeAlD
Cabergoline—ADRA1B—central nervous system—acquired immunodeficiency syndrome	0.00129	0.0116	CbGeAlD
Cabergoline—ADRA1D—central nervous system—acquired immunodeficiency syndrome	0.00126	0.0113	CbGeAlD
Cabergoline—DRD5—brain—acquired immunodeficiency syndrome	0.00125	0.0112	CbGeAlD
Cabergoline—DRD1—nervous system—acquired immunodeficiency syndrome	0.00125	0.0112	CbGeAlD
Cabergoline—DRD1—central nervous system—acquired immunodeficiency syndrome	0.0012	0.0108	CbGeAlD
Cabergoline—HTR1B—spinal cord—acquired immunodeficiency syndrome	0.0012	0.0108	CbGeAlD
Cabergoline—HTR2B—digestive system—acquired immunodeficiency syndrome	0.00118	0.0106	CbGeAlD
Cabergoline—HTR2C—spinal cord—acquired immunodeficiency syndrome	0.00115	0.0103	CbGeAlD
Cabergoline—HTR2B—blood—acquired immunodeficiency syndrome	0.00112	0.0101	CbGeAlD
Cabergoline—HTR2B—vagina—acquired immunodeficiency syndrome	0.00104	0.00934	CbGeAlD
Cabergoline—ADRB1—lung—acquired immunodeficiency syndrome	0.00103	0.00923	CbGeAlD
Cabergoline—ADRA1B—brain—acquired immunodeficiency syndrome	0.00102	0.00919	CbGeAlD
Cabergoline—HTR1B—nervous system—acquired immunodeficiency syndrome	0.00101	0.00908	CbGeAlD
Cabergoline—HTR7—digestive system—acquired immunodeficiency syndrome	0.00101	0.00906	CbGeAlD
Cabergoline—ADRA1D—brain—acquired immunodeficiency syndrome	0.001	0.00899	CbGeAlD
Cabergoline—ADRA1A—lymphoid tissue—acquired immunodeficiency syndrome	0.000985	0.00885	CbGeAlD
Cabergoline—HTR2B—lung—acquired immunodeficiency syndrome	0.000984	0.00883	CbGeAlD
Cabergoline—HTR1D—nervous system—acquired immunodeficiency syndrome	0.00098	0.00879	CbGeAlD
Cabergoline—HTR1B—central nervous system—acquired immunodeficiency syndrome	0.000974	0.00875	CbGeAlD
Cabergoline—HTR2C—nervous system—acquired immunodeficiency syndrome	0.00097	0.00871	CbGeAlD
Cabergoline—HTR1A—spinal cord—acquired immunodeficiency syndrome	0.000969	0.0087	CbGeAlD
Cabergoline—HTR7—blood—acquired immunodeficiency syndrome	0.000961	0.00863	CbGeAlD
Cabergoline—DRD1—brain—acquired immunodeficiency syndrome	0.000955	0.00857	CbGeAlD
Cabergoline—ADRB1—nervous system—acquired immunodeficiency syndrome	0.000952	0.00855	CbGeAlD
Cabergoline—HTR1D—central nervous system—acquired immunodeficiency syndrome	0.000943	0.00847	CbGeAlD
Cabergoline—HTR2C—central nervous system—acquired immunodeficiency syndrome	0.000934	0.00838	CbGeAlD
Cabergoline—ADRA1A—blood—acquired immunodeficiency syndrome	0.000927	0.00832	CbGeAlD
Cabergoline—HTR7—spinal cord—acquired immunodeficiency syndrome	0.000926	0.00831	CbGeAlD
Cabergoline—ADRB1—central nervous system—acquired immunodeficiency syndrome	0.000917	0.00823	CbGeAlD
Cabergoline—HTR2B—nervous system—acquired immunodeficiency syndrome	0.000911	0.00818	CbGeAlD
Cabergoline—HTR2A—retina—acquired immunodeficiency syndrome	0.000896	0.00804	CbGeAlD
Cabergoline—ADRA2C—blood—acquired immunodeficiency syndrome	0.000884	0.00793	CbGeAlD
Cabergoline—HTR2B—central nervous system—acquired immunodeficiency syndrome	0.000877	0.00788	CbGeAlD
Cabergoline—ADRA2C—spinal cord—acquired immunodeficiency syndrome	0.000851	0.00764	CbGeAlD
Cabergoline—HTR7—lung—acquired immunodeficiency syndrome	0.000843	0.00756	CbGeAlD
Cabergoline—ADRA2C—vagina—acquired immunodeficiency syndrome	0.000819	0.00735	CbGeAlD
Cabergoline—HTR1A—nervous system—acquired immunodeficiency syndrome	0.000817	0.00733	CbGeAlD
Cabergoline—DRD2—lung—acquired immunodeficiency syndrome	0.000797	0.00715	CbGeAlD
Cabergoline—HTR1A—central nervous system—acquired immunodeficiency syndrome	0.000786	0.00706	CbGeAlD
Cabergoline—HTR7—nervous system—acquired immunodeficiency syndrome	0.00078	0.00701	CbGeAlD
Cabergoline—ADRA2C—lung—acquired immunodeficiency syndrome	0.000775	0.00695	CbGeAlD
Cabergoline—HTR1B—brain—acquired immunodeficiency syndrome	0.000773	0.00694	CbGeAlD
Cabergoline—ADRA1A—nervous system—acquired immunodeficiency syndrome	0.000753	0.00676	CbGeAlD
Cabergoline—HTR7—central nervous system—acquired immunodeficiency syndrome	0.000751	0.00674	CbGeAlD
Cabergoline—HTR1D—brain—acquired immunodeficiency syndrome	0.000749	0.00672	CbGeAlD
Cabergoline—HTR2C—brain—acquired immunodeficiency syndrome	0.000742	0.00666	CbGeAlD
Cabergoline—DRD2—nervous system—acquired immunodeficiency syndrome	0.000738	0.00662	CbGeAlD
Cabergoline—ADRB1—brain—acquired immunodeficiency syndrome	0.000728	0.00653	CbGeAlD
Cabergoline—ADRA1A—central nervous system—acquired immunodeficiency syndrome	0.000725	0.00651	CbGeAlD
Cabergoline—ADRA2C—nervous system—acquired immunodeficiency syndrome	0.000717	0.00644	CbGeAlD
Cabergoline—DRD2—central nervous system—acquired immunodeficiency syndrome	0.00071	0.00638	CbGeAlD
Cabergoline—ADRA2A—blood—acquired immunodeficiency syndrome	0.000705	0.00633	CbGeAlD
Cabergoline—HTR2B—brain—acquired immunodeficiency syndrome	0.000697	0.00625	CbGeAlD
Cabergoline—ADRA2C—central nervous system—acquired immunodeficiency syndrome	0.000691	0.0062	CbGeAlD
Cabergoline—ADRA2A—spinal cord—acquired immunodeficiency syndrome	0.000679	0.0061	CbGeAlD
Cabergoline—HTR2B—lymph node—acquired immunodeficiency syndrome	0.000673	0.00604	CbGeAlD
Cabergoline—ADRA2A—vagina—acquired immunodeficiency syndrome	0.000654	0.00587	CbGeAlD
Cabergoline—HTR2A—digestive system—acquired immunodeficiency syndrome	0.000629	0.00565	CbGeAlD
Cabergoline—HTR1A—brain—acquired immunodeficiency syndrome	0.000624	0.0056	CbGeAlD
Cabergoline—ADRA2A—lung—acquired immunodeficiency syndrome	0.000618	0.00555	CbGeAlD
Cabergoline—HTR2A—blood—acquired immunodeficiency syndrome	0.000599	0.00538	CbGeAlD
Cabergoline—HTR7—brain—acquired immunodeficiency syndrome	0.000596	0.00535	CbGeAlD
Cabergoline—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000583	0.00523	CbGeAlD
Cabergoline—HTR2A—spinal cord—acquired immunodeficiency syndrome	0.000578	0.00518	CbGeAlD
Cabergoline—ADRA1A—brain—acquired immunodeficiency syndrome	0.000575	0.00516	CbGeAlD
Cabergoline—ADRA2A—nervous system—acquired immunodeficiency syndrome	0.000572	0.00514	CbGeAlD
Cabergoline—DRD2—brain—acquired immunodeficiency syndrome	0.000564	0.00506	CbGeAlD
Cabergoline—HTR2A—vagina—acquired immunodeficiency syndrome	0.000556	0.00499	CbGeAlD
Cabergoline—CYP3A4—blood—acquired immunodeficiency syndrome	0.000555	0.00498	CbGeAlD
Cabergoline—ADRA2A—central nervous system—acquired immunodeficiency syndrome	0.000551	0.00495	CbGeAlD
Cabergoline—ADRA2C—brain—acquired immunodeficiency syndrome	0.000548	0.00492	CbGeAlD
Cabergoline—ADRA2C—lymph node—acquired immunodeficiency syndrome	0.00053	0.00476	CbGeAlD
Cabergoline—HTR2A—lung—acquired immunodeficiency syndrome	0.000526	0.00472	CbGeAlD
Cabergoline—HTR2A—nervous system—acquired immunodeficiency syndrome	0.000487	0.00437	CbGeAlD
Cabergoline—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000471	0.00108	CcSEcCtD
Cabergoline—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.00047	0.00108	CcSEcCtD
Cabergoline—Syncope—Ritonavir—acquired immunodeficiency syndrome	0.00047	0.00108	CcSEcCtD
Cabergoline—HTR2A—central nervous system—acquired immunodeficiency syndrome	0.000469	0.00421	CbGeAlD
Cabergoline—Ill-defined disorder—Saquinavir—acquired immunodeficiency syndrome	0.000468	0.00108	CcSEcCtD
Cabergoline—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000468	0.00108	CcSEcCtD
Cabergoline—Nervousness—Lamivudine—acquired immunodeficiency syndrome	0.000467	0.00108	CcSEcCtD
Cabergoline—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.000467	0.00108	CcSEcCtD
Cabergoline—Confusional state—Delavirdine—acquired immunodeficiency syndrome	0.000466	0.00107	CcSEcCtD
Cabergoline—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000466	0.00107	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.000466	0.00107	CcSEcCtD
Cabergoline—Back pain—Lamivudine—acquired immunodeficiency syndrome	0.000466	0.00107	CcSEcCtD
Cabergoline—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000464	0.00107	CcSEcCtD
Cabergoline—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000464	0.00107	CcSEcCtD
Cabergoline—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.000463	0.00107	CcSEcCtD
Cabergoline—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000463	0.00107	CcSEcCtD
Cabergoline—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.000463	0.00106	CcSEcCtD
Cabergoline—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000463	0.00106	CcSEcCtD
Cabergoline—Anorexia—Efavirenz—acquired immunodeficiency syndrome	0.000461	0.00106	CcSEcCtD
Cabergoline—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.000461	0.00106	CcSEcCtD
Cabergoline—Rash—Didanosine—acquired immunodeficiency syndrome	0.00046	0.00106	CcSEcCtD
Cabergoline—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.00046	0.00106	CcSEcCtD
Cabergoline—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.00046	0.00106	CcSEcCtD
Cabergoline—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000459	0.00106	CcSEcCtD
Cabergoline—Headache—Didanosine—acquired immunodeficiency syndrome	0.000457	0.00105	CcSEcCtD
Cabergoline—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000456	0.00105	CcSEcCtD
Cabergoline—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000456	0.00105	CcSEcCtD
Cabergoline—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000455	0.00105	CcSEcCtD
Cabergoline—Malaise—Saquinavir—acquired immunodeficiency syndrome	0.000455	0.00105	CcSEcCtD
Cabergoline—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000455	0.00105	CcSEcCtD
Cabergoline—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000454	0.00105	CcSEcCtD
Cabergoline—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000453	0.00104	CcSEcCtD
Cabergoline—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.000453	0.00104	CcSEcCtD
Cabergoline—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000453	0.00104	CcSEcCtD
Cabergoline—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.000452	0.00104	CcSEcCtD
Cabergoline—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000451	0.00404	CbGeAlD
Cabergoline—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.00045	0.00104	CcSEcCtD
Cabergoline—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.00045	0.00104	CcSEcCtD
Cabergoline—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000449	0.00103	CcSEcCtD
Cabergoline—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000449	0.00103	CcSEcCtD
Cabergoline—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000448	0.00103	CcSEcCtD
Cabergoline—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000448	0.00103	CcSEcCtD
Cabergoline—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000447	0.00103	CcSEcCtD
Cabergoline—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	0.000447	0.00103	CcSEcCtD
Cabergoline—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000446	0.00103	CcSEcCtD
Cabergoline—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000445	0.00102	CcSEcCtD
Cabergoline—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000445	0.00102	CcSEcCtD
Cabergoline—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000443	0.00102	CcSEcCtD
Cabergoline—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000441	0.00102	CcSEcCtD
Cabergoline—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000441	0.00102	CcSEcCtD
Cabergoline—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000441	0.00101	CcSEcCtD
Cabergoline—Discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000441	0.00101	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000441	0.00101	CcSEcCtD
Cabergoline—Pain—Indinavir—acquired immunodeficiency syndrome	0.000438	0.00101	CcSEcCtD
Cabergoline—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000438	0.00101	CcSEcCtD
Cabergoline—ADRA2A—brain—acquired immunodeficiency syndrome	0.000437	0.00393	CbGeAlD
Cabergoline—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000437	0.00101	CcSEcCtD
Cabergoline—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000436	0.001	CcSEcCtD
Cabergoline—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000436	0.001	CcSEcCtD
Cabergoline—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000435	0.001	CcSEcCtD
Cabergoline—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000435	0.001	CcSEcCtD
Cabergoline—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000434	0.000999	CcSEcCtD
Cabergoline—Malaise—Lamivudine—acquired immunodeficiency syndrome	0.000434	0.000999	CcSEcCtD
Cabergoline—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000434	0.00389	CbGeAlD
Cabergoline—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000433	0.000997	CcSEcCtD
Cabergoline—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000433	0.000997	CcSEcCtD
Cabergoline—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000432	0.000995	CcSEcCtD
Cabergoline—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000432	0.000995	CcSEcCtD
Cabergoline—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000432	0.000993	CcSEcCtD
Cabergoline—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000431	0.000993	CcSEcCtD
Cabergoline—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000431	0.000992	CcSEcCtD
Cabergoline—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.00043	0.000989	CcSEcCtD
Cabergoline—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.00043	0.000988	CcSEcCtD
Cabergoline—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000428	0.000985	CcSEcCtD
Cabergoline—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000428	0.000984	CcSEcCtD
Cabergoline—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000427	0.000982	CcSEcCtD
Cabergoline—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000426	0.000979	CcSEcCtD
Cabergoline—Discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000424	0.000977	CcSEcCtD
Cabergoline—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000423	0.000973	CcSEcCtD
Cabergoline—ADRA2A—lymph node—acquired immunodeficiency syndrome	0.000423	0.00379	CbGeAlD
Cabergoline—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000422	0.00097	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000422	0.00097	CcSEcCtD
Cabergoline—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000421	0.000969	CcSEcCtD
Cabergoline—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.00042	0.000967	CcSEcCtD
Cabergoline—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.00042	0.000967	CcSEcCtD
Cabergoline—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.00042	0.000966	CcSEcCtD
Cabergoline—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000419	0.000963	CcSEcCtD
Cabergoline—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000418	0.000963	CcSEcCtD
Cabergoline—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000418	0.000963	CcSEcCtD
Cabergoline—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000417	0.000959	CcSEcCtD
Cabergoline—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000417	0.000959	CcSEcCtD
Cabergoline—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000415	0.000956	CcSEcCtD
Cabergoline—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000415	0.000955	CcSEcCtD
Cabergoline—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000414	0.000952	CcSEcCtD
Cabergoline—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000413	0.000951	CcSEcCtD
Cabergoline—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000413	0.000951	CcSEcCtD
Cabergoline—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000413	0.000951	CcSEcCtD
Cabergoline—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000413	0.00095	CcSEcCtD
Cabergoline—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000412	0.000949	CcSEcCtD
Cabergoline—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000412	0.000949	CcSEcCtD
Cabergoline—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000412	0.000948	CcSEcCtD
Cabergoline—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000411	0.000946	CcSEcCtD
Cabergoline—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000411	0.000945	CcSEcCtD
Cabergoline—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.00041	0.000943	CcSEcCtD
Cabergoline—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000408	0.00094	CcSEcCtD
Cabergoline—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000408	0.000938	CcSEcCtD
Cabergoline—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000407	0.000937	CcSEcCtD
Cabergoline—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000405	0.000932	CcSEcCtD
Cabergoline—Discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000405	0.000932	CcSEcCtD
Cabergoline—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000405	0.000931	CcSEcCtD
Cabergoline—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000404	0.000929	CcSEcCtD
Cabergoline—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000403	0.000926	CcSEcCtD
Cabergoline—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000402	0.000925	CcSEcCtD
Cabergoline—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000401	0.000922	CcSEcCtD
Cabergoline—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.0004	0.000921	CcSEcCtD
Cabergoline—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.0004	0.000921	CcSEcCtD
Cabergoline—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.0004	0.00092	CcSEcCtD
Cabergoline—Rash—Stavudine—acquired immunodeficiency syndrome	0.000399	0.000919	CcSEcCtD
Cabergoline—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000399	0.000918	CcSEcCtD
Cabergoline—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000399	0.000918	CcSEcCtD
Cabergoline—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000398	0.000917	CcSEcCtD
Cabergoline—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000398	0.000916	CcSEcCtD
Cabergoline—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000398	0.000915	CcSEcCtD
Cabergoline—Headache—Stavudine—acquired immunodeficiency syndrome	0.000397	0.000913	CcSEcCtD
Cabergoline—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000397	0.000913	CcSEcCtD
Cabergoline—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.000396	0.000911	CcSEcCtD
Cabergoline—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000396	0.00091	CcSEcCtD
Cabergoline—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000396	0.00091	CcSEcCtD
Cabergoline—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000395	0.00091	CcSEcCtD
Cabergoline—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000395	0.000909	CcSEcCtD
Cabergoline—Rash—Abacavir—acquired immunodeficiency syndrome	0.000393	0.000905	CcSEcCtD
Cabergoline—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000393	0.000904	CcSEcCtD
Cabergoline—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000393	0.000904	CcSEcCtD
Cabergoline—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.000393	0.000903	CcSEcCtD
Cabergoline—Headache—Abacavir—acquired immunodeficiency syndrome	0.000391	0.000899	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.00039	0.000897	CcSEcCtD
Cabergoline—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000389	0.000896	CcSEcCtD
Cabergoline—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000389	0.000896	CcSEcCtD
Cabergoline—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000387	0.00089	CcSEcCtD
Cabergoline—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000386	0.000889	CcSEcCtD
Cabergoline—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000385	0.000885	CcSEcCtD
Cabergoline—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000384	0.000884	CcSEcCtD
Cabergoline—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000382	0.00088	CcSEcCtD
Cabergoline—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000381	0.000878	CcSEcCtD
Cabergoline—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000381	0.000877	CcSEcCtD
Cabergoline—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.00038	0.000875	CcSEcCtD
Cabergoline—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.00038	0.000874	CcSEcCtD
Cabergoline—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000378	0.000871	CcSEcCtD
Cabergoline—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000377	0.000868	CcSEcCtD
Cabergoline—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000377	0.000868	CcSEcCtD
Cabergoline—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000377	0.000867	CcSEcCtD
Cabergoline—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000377	0.000866	CcSEcCtD
Cabergoline—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000376	0.000865	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000375	0.000863	CcSEcCtD
Cabergoline—Anorexia—Lamivudine—acquired immunodeficiency syndrome	0.000374	0.000862	CcSEcCtD
Cabergoline—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000372	0.000857	CcSEcCtD
Cabergoline—HTR2A—brain—acquired immunodeficiency syndrome	0.000372	0.00334	CbGeAlD
Cabergoline—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.000372	0.000856	CcSEcCtD
Cabergoline—Nausea—Abacavir—acquired immunodeficiency syndrome	0.00037	0.000852	CcSEcCtD
Cabergoline—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.00037	0.000851	CcSEcCtD
Cabergoline—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000369	0.000849	CcSEcCtD
Cabergoline—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000367	0.000845	CcSEcCtD
Cabergoline—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000367	0.000845	CcSEcCtD
Cabergoline—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000367	0.000845	CcSEcCtD
Cabergoline—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000366	0.000842	CcSEcCtD
Cabergoline—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000366	0.000842	CcSEcCtD
Cabergoline—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000366	0.000842	CcSEcCtD
Cabergoline—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000366	0.000842	CcSEcCtD
Cabergoline—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000364	0.000837	CcSEcCtD
Cabergoline—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000362	0.000834	CcSEcCtD
Cabergoline—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000362	0.000833	CcSEcCtD
Cabergoline—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000358	0.000824	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000358	0.000824	CcSEcCtD
Cabergoline—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000356	0.00082	CcSEcCtD
Cabergoline—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000355	0.000818	CcSEcCtD
Cabergoline—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000355	0.000817	CcSEcCtD
Cabergoline—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000353	0.000812	CcSEcCtD
Cabergoline—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000353	0.000811	CcSEcCtD
Cabergoline—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000352	0.00081	CcSEcCtD
Cabergoline—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000352	0.00081	CcSEcCtD
Cabergoline—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.00035	0.000806	CcSEcCtD
Cabergoline—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.00035	0.000806	CcSEcCtD
Cabergoline—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.00035	0.000805	CcSEcCtD
Cabergoline—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.00035	0.000805	CcSEcCtD
Cabergoline—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000349	0.000804	CcSEcCtD
Cabergoline—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000347	0.000798	CcSEcCtD
Cabergoline—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000347	0.000798	CcSEcCtD
Cabergoline—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000347	0.000798	CcSEcCtD
Cabergoline—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000346	0.000796	CcSEcCtD
Cabergoline—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000345	0.000793	CcSEcCtD
Cabergoline—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000342	0.000787	CcSEcCtD
Cabergoline—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.000341	0.000786	CcSEcCtD
Cabergoline—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000341	0.000784	CcSEcCtD
Cabergoline—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000339	0.000781	CcSEcCtD
Cabergoline—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000339	0.000779	CcSEcCtD
Cabergoline—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000338	0.000779	CcSEcCtD
Cabergoline—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000338	0.000778	CcSEcCtD
Cabergoline—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000337	0.000775	CcSEcCtD
Cabergoline—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000336	0.000773	CcSEcCtD
Cabergoline—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000336	0.000773	CcSEcCtD
Cabergoline—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000332	0.000764	CcSEcCtD
Cabergoline—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000331	0.000761	CcSEcCtD
Cabergoline—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000327	0.000753	CcSEcCtD
Cabergoline—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000327	0.000752	CcSEcCtD
Cabergoline—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000326	0.000749	CcSEcCtD
Cabergoline—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000325	0.000749	CcSEcCtD
Cabergoline—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000324	0.000745	CcSEcCtD
Cabergoline—Rash—Indinavir—acquired immunodeficiency syndrome	0.000323	0.000743	CcSEcCtD
Cabergoline—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000322	0.000742	CcSEcCtD
Cabergoline—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000321	0.000739	CcSEcCtD
Cabergoline—Headache—Indinavir—acquired immunodeficiency syndrome	0.000321	0.000738	CcSEcCtD
Cabergoline—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.00032	0.000736	CcSEcCtD
Cabergoline—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000317	0.000728	CcSEcCtD
Cabergoline—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000315	0.000725	CcSEcCtD
Cabergoline—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000311	0.000715	CcSEcCtD
Cabergoline—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000307	0.000707	CcSEcCtD
Cabergoline—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000307	0.000706	CcSEcCtD
Cabergoline—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000306	0.000704	CcSEcCtD
Cabergoline—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000305	0.000702	CcSEcCtD
Cabergoline—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000305	0.000701	CcSEcCtD
Cabergoline—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000304	0.000699	CcSEcCtD
Cabergoline—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000303	0.000698	CcSEcCtD
Cabergoline—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000303	0.000697	CcSEcCtD
Cabergoline—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000303	0.000696	CcSEcCtD
Cabergoline—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000295	0.00068	CcSEcCtD
Cabergoline—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000294	0.000677	CcSEcCtD
Cabergoline—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000293	0.000674	CcSEcCtD
Cabergoline—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000292	0.000671	CcSEcCtD
Cabergoline—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000291	0.000671	CcSEcCtD
Cabergoline—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000291	0.00067	CcSEcCtD
Cabergoline—Headache—Delavirdine—acquired immunodeficiency syndrome	0.00029	0.000667	CcSEcCtD
Cabergoline—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000289	0.000666	CcSEcCtD
Cabergoline—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000287	0.000661	CcSEcCtD
Cabergoline—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000283	0.000651	CcSEcCtD
Cabergoline—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000282	0.000649	CcSEcCtD
Cabergoline—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000282	0.000648	CcSEcCtD
Cabergoline—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000278	0.00064	CcSEcCtD
Cabergoline—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000275	0.000632	CcSEcCtD
Cabergoline—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000272	0.000627	CcSEcCtD
Cabergoline—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000272	0.000626	CcSEcCtD
Cabergoline—Rash—Ritonavir—acquired immunodeficiency syndrome	0.00027	0.000621	CcSEcCtD
Cabergoline—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.00027	0.00062	CcSEcCtD
Cabergoline—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000269	0.000618	CcSEcCtD
Cabergoline—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000268	0.000617	CcSEcCtD
Cabergoline—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000262	0.000602	CcSEcCtD
Cabergoline—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.00026	0.000598	CcSEcCtD
Cabergoline—Rash—Saquinavir—acquired immunodeficiency syndrome	0.00026	0.000597	CcSEcCtD
Cabergoline—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000259	0.000597	CcSEcCtD
Cabergoline—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000258	0.000594	CcSEcCtD
Cabergoline—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000254	0.000585	CcSEcCtD
Cabergoline—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.00025	0.000575	CcSEcCtD
Cabergoline—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000248	0.00057	CcSEcCtD
Cabergoline—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000247	0.000569	CcSEcCtD
Cabergoline—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000246	0.000566	CcSEcCtD
Cabergoline—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000245	0.000563	CcSEcCtD
Cabergoline—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000233	0.000537	CcSEcCtD
Cabergoline—HTR2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.44e-05	0.000292	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.42e-05	0.000291	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.42e-05	0.000291	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.41e-05	0.00029	CbGpPWpGaD
Cabergoline—ADRA1B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	4.41e-05	0.00029	CbGpPWpGaD
Cabergoline—ADRB1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.39e-05	0.000289	CbGpPWpGaD
Cabergoline—ADRA2B—Hemostasis—IL2—acquired immunodeficiency syndrome	4.38e-05	0.000288	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	4.37e-05	0.000288	CbGpPWpGaD
Cabergoline—HTR2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.37e-05	0.000287	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.35e-05	0.000286	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.35e-05	0.000286	CbGpPWpGaD
Cabergoline—ADRA1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.34e-05	0.000286	CbGpPWpGaD
Cabergoline—DRD5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.34e-05	0.000286	CbGpPWpGaD
Cabergoline—ADRB2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.3e-05	0.000282	CbGpPWpGaD
Cabergoline—ADRA1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.28e-05	0.000281	CbGpPWpGaD
Cabergoline—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	4.26e-05	0.00028	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.26e-05	0.00028	CbGpPWpGaD
Cabergoline—DRD5—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.25e-05	0.000279	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.24e-05	0.000279	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.21e-05	0.000277	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.21e-05	0.000277	CbGpPWpGaD
Cabergoline—HTR1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.2e-05	0.000276	CbGpPWpGaD
Cabergoline—HTR2C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.18e-05	0.000275	CbGpPWpGaD
Cabergoline—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	4.17e-05	0.000274	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.15e-05	0.000273	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.15e-05	0.000273	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.15e-05	0.000273	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.15e-05	0.000273	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.12e-05	0.000271	CbGpPWpGaD
Cabergoline—ADRA2A—Hemostasis—ALB—acquired immunodeficiency syndrome	4.1e-05	0.00027	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4.09e-05	0.000269	CbGpPWpGaD
Cabergoline—ADRA2C—Hemostasis—IL2—acquired immunodeficiency syndrome	4.09e-05	0.000269	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.06e-05	0.000267	CbGpPWpGaD
Cabergoline—DRD2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	4.06e-05	0.000267	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	4.06e-05	0.000267	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.06e-05	0.000267	CbGpPWpGaD
Cabergoline—ADRA2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.04e-05	0.000265	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	4.03e-05	0.000265	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4.03e-05	0.000265	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.03e-05	0.000265	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4e-05	0.000263	CbGpPWpGaD
Cabergoline—HTR2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	4e-05	0.000263	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.99e-05	0.000262	CbGpPWpGaD
Cabergoline—ADRA2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.98e-05	0.000261	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.97e-05	0.000261	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.94e-05	0.000259	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.94e-05	0.000259	CbGpPWpGaD
Cabergoline—ADRA1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.91e-05	0.000257	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.89e-05	0.000255	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.85e-05	0.000253	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.83e-05	0.000252	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.79e-05	0.000249	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.79e-05	0.000249	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.75e-05	0.000247	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.75e-05	0.000247	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.74e-05	0.000246	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.73e-05	0.000245	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.72e-05	0.000244	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.7e-05	0.000243	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.7e-05	0.000243	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.69e-05	0.000243	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.69e-05	0.000242	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.68e-05	0.000242	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.67e-05	0.000241	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.66e-05	0.000241	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.66e-05	0.000241	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.64e-05	0.000239	CbGpPWpGaD
Cabergoline—ADRA2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.64e-05	0.000239	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.63e-05	0.000239	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.62e-05	0.000238	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.62e-05	0.000238	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.62e-05	0.000238	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.61e-05	0.000237	CbGpPWpGaD
Cabergoline—HTR7—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.61e-05	0.000237	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.6e-05	0.000237	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.6e-05	0.000237	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.6e-05	0.000237	CbGpPWpGaD
Cabergoline—HTR1D—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.58e-05	0.000236	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.56e-05	0.000234	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.56e-05	0.000234	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.55e-05	0.000234	CbGpPWpGaD
Cabergoline—HTR1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.51e-05	0.000231	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.5e-05	0.00023	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.5e-05	0.00023	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.5e-05	0.00023	CbGpPWpGaD
Cabergoline—DRD4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.45e-05	0.000227	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	3.45e-05	0.000227	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.45e-05	0.000227	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.45e-05	0.000227	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.4e-05	0.000223	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.38e-05	0.000222	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.35e-05	0.00022	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.35e-05	0.00022	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.35e-05	0.00022	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.33e-05	0.000219	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.33e-05	0.000219	CbGpPWpGaD
Cabergoline—ADRA2A—Hemostasis—IL2—acquired immunodeficiency syndrome	3.32e-05	0.000219	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.3e-05	0.000217	CbGpPWpGaD
Cabergoline—HTR2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.3e-05	0.000217	CbGpPWpGaD
Cabergoline—HTR7—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.28e-05	0.000215	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.26e-05	0.000214	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.26e-05	0.000214	CbGpPWpGaD
Cabergoline—HTR1D—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.25e-05	0.000214	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.21e-05	0.000211	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.2e-05	0.000211	CbGpPWpGaD
Cabergoline—HTR1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.19e-05	0.000209	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.18e-05	0.000209	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.18e-05	0.000209	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.16e-05	0.000208	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.16e-05	0.000208	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.16e-05	0.000207	CbGpPWpGaD
Cabergoline—DRD4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.14e-05	0.000206	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.13e-05	0.000206	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.13e-05	0.000206	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.11e-05	0.000205	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.11e-05	0.000205	CbGpPWpGaD
Cabergoline—DRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.11e-05	0.000204	CbGpPWpGaD
Cabergoline—DRD3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.07e-05	0.000202	CbGpPWpGaD
Cabergoline—ADRA1D—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.07e-05	0.000202	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.06e-05	0.000201	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.06e-05	0.000201	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.06e-05	0.000201	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.03e-05	0.000199	CbGpPWpGaD
Cabergoline—HTR2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.99e-05	0.000197	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.89e-05	0.00019	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.88e-05	0.000189	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.85e-05	0.000188	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.85e-05	0.000187	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.85e-05	0.000187	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.85e-05	0.000187	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.85e-05	0.000187	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.84e-05	0.000186	CbGpPWpGaD
Cabergoline—DRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.82e-05	0.000186	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.82e-05	0.000185	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.81e-05	0.000185	CbGpPWpGaD
Cabergoline—ADRB1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.79e-05	0.000184	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.78e-05	0.000183	CbGpPWpGaD
Cabergoline—DRD3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.78e-05	0.000183	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.77e-05	0.000182	CbGpPWpGaD
Cabergoline—ADRA2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.77e-05	0.000182	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.75e-05	0.000181	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.74e-05	0.00018	CbGpPWpGaD
Cabergoline—ADRB2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.73e-05	0.00018	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.71e-05	0.000178	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.7e-05	0.000177	CbGpPWpGaD
Cabergoline—HTR1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.67e-05	0.000176	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.67e-05	0.000175	CbGpPWpGaD
Cabergoline—HTR2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.66e-05	0.000175	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.63e-05	0.000173	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.62e-05	0.000172	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.59e-05	0.000171	CbGpPWpGaD
Cabergoline—ADRA2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.59e-05	0.00017	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.58e-05	0.00017	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.57e-05	0.000169	CbGpPWpGaD
Cabergoline—ADRA1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.55e-05	0.000167	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.54e-05	0.000167	CbGpPWpGaD
Cabergoline—ADRB1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.54e-05	0.000167	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.51e-05	0.000165	CbGpPWpGaD
Cabergoline—DRD5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.51e-05	0.000165	CbGpPWpGaD
Cabergoline—DRD5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.5e-05	0.000164	CbGpPWpGaD
Cabergoline—ADRB2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.48e-05	0.000163	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.48e-05	0.000163	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.47e-05	0.000162	CbGpPWpGaD
Cabergoline—HTR1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.43e-05	0.00016	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.42e-05	0.000159	CbGpPWpGaD
Cabergoline—HTR2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.41e-05	0.000159	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.4e-05	0.000158	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.38e-05	0.000157	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.38e-05	0.000156	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.36e-05	0.000155	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.35e-05	0.000154	CbGpPWpGaD
Cabergoline—DRD2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.35e-05	0.000154	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.34e-05	0.000154	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.33e-05	0.000153	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.31e-05	0.000152	CbGpPWpGaD
Cabergoline—HTR2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.31e-05	0.000152	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.3e-05	0.000151	CbGpPWpGaD
Cabergoline—ADRA1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.26e-05	0.000149	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.18e-05	0.000143	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.16e-05	0.000142	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.14e-05	0.000141	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.13e-05	0.00014	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.13e-05	0.00014	CbGpPWpGaD
Cabergoline—ADRA2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.1e-05	0.000138	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.1e-05	0.000138	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.1e-05	0.000138	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.05e-05	0.000135	CbGpPWpGaD
Cabergoline—ADRA2C—Metabolism—ALB—acquired immunodeficiency syndrome	2.05e-05	0.000135	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.95e-05	0.000128	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.93e-05	0.000127	CbGpPWpGaD
Cabergoline—HTR7—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.93e-05	0.000127	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.92e-05	0.000126	CbGpPWpGaD
Cabergoline—HTR1D—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.91e-05	0.000126	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.91e-05	0.000125	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.88e-05	0.000124	CbGpPWpGaD
Cabergoline—HTR1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.87e-05	0.000123	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.85e-05	0.000122	CbGpPWpGaD
Cabergoline—DRD4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.84e-05	0.000121	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.77e-05	0.000116	CbGpPWpGaD
Cabergoline—HTR2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.76e-05	0.000116	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.67e-05	0.00011	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—ALB—acquired immunodeficiency syndrome	1.66e-05	0.000109	CbGpPWpGaD
Cabergoline—DRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.66e-05	0.000109	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.65e-05	0.000108	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.65e-05	0.000108	CbGpPWpGaD
Cabergoline—DRD3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.64e-05	0.000108	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.64e-05	0.000108	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.5e-05	9.86e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.49e-05	9.81e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.49e-05	9.77e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.48e-05	9.72e-05	CbGpPWpGaD
Cabergoline—DRD5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.47e-05	9.7e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.47e-05	9.64e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.46e-05	9.59e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.43e-05	9.43e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.43e-05	9.38e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.43e-05	9.38e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.42e-05	9.33e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.39e-05	9.12e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.38e-05	9.08e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.37e-05	8.98e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.36e-05	8.93e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.26e-05	8.28e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.25e-05	8.24e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.24e-05	8.14e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.23e-05	8.1e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.21e-05	7.97e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.21e-05	7.93e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.14e-05	7.48e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.13e-05	7.43e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.13e-05	7.41e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.12e-05	7.37e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.11e-05	7.27e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.09e-05	7.16e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.04e-05	6.83e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.8e-06	6.44e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.67e-06	6.36e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.67e-06	6.36e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.81e-06	5.79e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.73e-06	5.74e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.62e-06	5.67e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.43e-06	5.54e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.38e-06	5.51e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.15e-06	5.36e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.03e-06	5.28e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.4e-06	4.86e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.28e-06	4.79e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.13e-06	4.69e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	7.08e-06	4.66e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.62e-06	4.35e-05	CbGpPWpGaD
